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Abstract
Background and Aims: Variant in glucokinase regulatory protein (GCKR), associated with lipid and glucose traits, has been
suggested to affect fatty liver infiltration. We aimed to assess whether GCKR rs780094 CRT SNP influences the expression of
steatosis, lobular inflammation and fibrosis in NAFLD patients, after correction for PNPLA3 genotype.
Methods: In 366 consecutive NAFLD patients (197 from Sicily, and 169 from center/northern Italy), we assessed
anthropometric, biochemical and metabolic features; liver biopsy was scored according to Kleiner. PNPLA3 rs738409 C.G
and GCKR rs780094 C.T single nucleotide polymorphisms were also assessed.
Results: At multivariate logistic regression analysis in the entire NAFLD cohort, the presence of significant liver fibrosis (.F1)
was independently linked to high HOMA (OR 1.12, 95% CI 1.01–1.23, p= 0.02), NAFLD activity score $5 (OR 4.09, 95% CI
2.45–6.81, p,0.001), and GCKR C.T SNP (OR 2.06, 95% CI 1.43–2.98, p,0.001). Similar results were observed considering
separately the two different NAFLD cohorts. GCKR C.T SNP was also associated with higher serum triglycerides (ANOVA,
p = 0.02) in the entire cohort.
Conclusions: In patients with NAFLD, GCKR rs780094 C.T is associated with the severity of liver fibrosis and with higher
serum triglyceride levels.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a frequent and
growing cause of chronic liver disease [1,2], affecting about 20%–
30% of the general population worldwide [3]. Patients with
NAFLD, and especially those with non-alcoholic steatohepatitis
(NASH), are at risk of progression to cirrhosis and its complica-
tions [1,4], presenting also a high rate of cancer and cardiovas-
cular events [5] compared to subjects without fatty liver. Classical
risk factors for liver disease severity and its progression are obesity,
insulin resistance (IR) and necroinflammation [6–9].
The above-mentioned conventional risk factors do not entirely
explain the occurrence and severity of NAFLD, suggesting that a
genetic background might also modulate the spectrum of liver
disease and its progression. Accordingly, the severity of disease has
been variably associated with different single nucleotide polymor-
phisms (SNPs) in genes involved in metabolic homeostasis,
inflammation, oxidative stress and fibrogenesis [10]. In this
context, the patatin-like phospholipase-3 (PNPLA3)/adiponutrin,
rs738409 C.G SNP remains the most validated risk gene [11–
18].
Besides the classical PNPLA3, a recent genome wide study
identified other genetic variants associated with computerized
tomography (TC)-proven hepatic steatosis in individuals of
European ancestry, and validated the results in 592 subjects with
biopsy-proven NAFLD from the NASH Clinical Research
Network (NASH CRN) database [19]. Among these gene variants,
the glucokinase regulatory protein (GCKR) has been further
confirmed as linked with steatosis (identified either by ultrasonog-
raphy, by magnetic resonance, or by computed tomography) in
children, in obese patients, and in populations of different ethnicity
[20–22]. GCKR seems to interfere with glucose and lipid
homeostasis by regulating glucose storage/disposal and by
providing substrates for de novo lipogenesis via inhibition of
glucokinase, but its potential association with the severity of liver
damage has never been tested
Having this in mind, the main outcome of this study was to assess
whether GCKR rs780094 was associated with the histological
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features of liver damage in patients with biopsy-proven NAFLD,
after correction for PNPLA3 genotype.
Patients and Methods
Patients
We analyzed data from 366 prospectively recruited Italian
patients with a clinical and histological diagnosis of NAFLD, and
with blood samples available for genetic analyses. The study
cohort included 197 patients from the Gastrointestinal & Liver
Unit of the Palermo University Hospital, and 169 central/
northern Italy patients from the Department of Internal Medicine
Catholic University of the Sacred Heart Rome (n = 114), and from
the Gastro-hepatology Division of the University Hospital Torino
(n = 55). Other causes of liver disease were ruled out, including
alcohol intake (.20 g/day) evaluated by a questionnaire, viral and
autoimmune hepatitis, hereditary hemochromatosis and alpha1-
antitrypsin deficiency. Patients with advanced cirrhosis, hepato-
cellular carcinoma and current use of steatosis inducing drugs were
excluded.
The study was carried out in accordance with the principles of
the Helsinki Declaration, and with local and national laws.
Approval was obtained from the hospital Internal Review Boards
and their Ethics Committees (UOC Gastroenterologia, AOUP
Policlinico of Palermo, Institute of Internal Medicine, Catholic
University of the Sacred Heart, Rome, and Division of Gastro-
Hepatology, San Giovanni Battista Hospital, University of
Torino), and written informed consent for the study was obtained
from all patients.
Clinical and Laboratory Assessment
Clinical and anthropometric data were collected at the time of
liver biopsy. Body mass index (BMI) was calculated on the basis of
weight in kilograms and height in meters. The diagnosis of arterial
hypertension was based on the following criteria: systolic blood
pressure $135 mm Hg and/or diastolic blood pressure
$85 mm Hg (measured three times within 30 minutes, in the
sitting position and using a brachial sphygmomanometer), or use
of blood-pressure-lowering agents. The diagnosis of type 2 diabetes
was based on the revised criteria of the American Diabetes
Association, using a value of fasting cut-off value of blood glucose
$126 mg/dl on at least two occasions [23]. In patients with a
previous diagnosis of type 2 diabetes, current therapy with insulin
or oral hypoglycemic agents was documented.
A 12-hour overnight fasting blood sample was drawn at the time
of biopsy to determine serum levels of ALT, total cholesterol,
HDL-cholesterol, triglycerides, plasma glucose and insulin con-
centrations. IR was assessed by homeostasis model assessment
(HOMA), using the following equation [24]: Insulin resistance
(HOMA-IR) = Fasting insulin (mU/mL)6Fasting glucose (mmol/
L)/22.5. [25]. HOMAbeta was also assessed as expression of
pancreatic beta-cell function [26]
Genetic Analyses
DNA was purified using the QIAmp blood Mini Kit (Qiagen,
Mainz, Germany) and DNA samples were quantified using
spectrophotometric determination. Genotyping for PNPLA3
(rs738409), and GCKR (rs780094) was carried out using the
TaqMan SNP genotyping allelic discrimination method (Applied
Biosystems, Foster City, CA, USA). Commercial genotyping
assays were available for the following SNPs: rs738409 (cat.
C_7241_10), rs780094 (cat. C_2862873_10).
The genotyping call was done with SDS software v.1.3.0 (ABI
Prism 7500, Foster City, CA, USA). Genotyping was conducted in
a blinded fashion relative to patient characteristics.
Assessment of Histology
Slides were coded and read at each clinical center by one expert
pathologist, who was unaware of patients’ identity and history. A
minimum 15 mm-length of the biopsy specimen or the presence of
at least 10 complete portal tracts was required [27]. Steatosis was
assessed as the percentage of hepatocytes containing fat droplets
(minimum 5%) and evaluated as a continuous variable. Kleiner
classification [28] was used to compute steatosis, balloning and
lobular inflammation, and to stage fibrosis from 0 to 4. NASH was
considered to be present when the NAFLD activity score (NAS)
was $5 [28].
Statistics
Continuous variables were summarized as mean 6 standard
deviation, and categorical variables as frequency and percentage.
The t-test, ANOVA test, and chi-square test were used when
appropriate.
Multiple logistic regression models were used to assess the
factors independently associated with severe steatosis, NAS $5,
and significant fibrosis. In the first model, the dependent variable
was steatosis, coded as 0 = mild-moderate (steatosis grade 1–2),
1 = severe (steatosis grade 3). In the second model, the dependent
variable was NAS $5, coded as 0 = NAS,5 or 1 = NAS $5. In
the third model, the dependent variable was fibrosis, coded as
0 = no significant fibrosis (F0–F1) or 1 = significant fibrosis (.F1).
As candidate risk factors, we selected age, gender, BMI, the
baseline levels of ALT, triglycerides, total and HDL cholesterol,
blood glucose, insulin, HOMA score, the presence of diabetes,
arterial hypertension, PNPLA3 rs738409, GCKR rs780094,
steatosis, lobular inflammation and fibrosis.
In all models, in agreement with literature data, we compared
patients homozygous for PNPLA3 G risk allele to all other variants
[14], while an additive model was used GCKR C.T SNP [19].
To avoid the effect of colinearity, diabetes, HOMA score, blood
glucose and insulin levels, or ALT levels and lobular inflammation
were not included in the same multivariate model. Variables
associated with the dependent variable at univariate analysis
(probability threshold, p#0.10) were included in the multivariate
regression models; PNPLA3 and GCKR SNPs, were forced into
the models when not significant associated to the tested dependent
variable. Regression analyses were performed using PROC
LOGISTIC, PROC REG, and subroutines in SAS [29].
Results
Patient Features and Histology
The baseline characteristics of the 197 Sicilian and the 169
Center/Northern Italian NAFLD patients are shown in Table 1.
Patients from Sicily were slightly older and with a moderately
lower prevalence of males, were more likely to be obese and to
have more severe steatosis and lobular inflammation compared to
Center/Northern Italian patients. Nevertheless, histological stag-
ing was similar in the two cohorts and significant fibrosis (.F1)
was present in approximately half of the patients.
The prevalence of GCKR rs780094 CC, CT and TT genotypes
was 16.4%, 48.9% and 34.7% in the entire cohort. When split
according to center (Sicily vs. Center/Northern Italy) the
prevalence of the single SNPs was similar (16.2%, 50.3% and
33.5% in the Sicilian cohort, vs. 16.6%, 47.3% and 36.1%;
p = 0.98). Similarly, the prevalence of PNPLA3 rs738409 CC, CG
GCKR and Liver Fibrosis in NAFLD
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and GG genotypes was 31.5%, 47.7% and 20.8% in the Sicilian
cohort, and 31.9%, 46.7% and 21.4% in the Center/Northern
Italy cohort (p = 0.98).
Genetic frequencies of the two polymorphisms fit with Hardy–
Weinberg equilibrium.
Influence of GCKR Genotype on Metabolic and
Biochemical Parameters
The association of the rs780094 GCKR CRT genotype with
anthropometric, metabolic and biochemical parameters in the
entire cohort is shown in Table 2. The only significant association
was between the TT genotype and higher triglyceride levels,
although independent of age, gender distribution, and BMI. When
split according to center, broadly similar data were observed in the
Center/Northern Italian cohort, where an association between
GCKR TT genotype and higher blood glucose levels was also
observed (85.5611.6 for CC, 96.7624.4 for CT, 96.4620 for TT;
p = 0.03). By contrast, in the Sicilian cohort the rs780094 genotype
was not associated with abnormal triglyceride levels.
Factors Associated with Histological Features
In the entire cohort, multivariate logistic regression analysis
showed that high BMI (OR 1.10, 95% CI 1.04–1.117, p= 0.001),
high HOMA considered as continuous variable (OR 1.08, 95% CI
1.00–1.17, p= 0.04), and PNPLA3 GG (OR 1.97, 95% CI 1.11–
3.51, p= 0.02) were independently associated with severe steatosis
(table 3 upper panel). Similar results were observed when analyses
were split by center (table 3 upper panel).
In the whole NAFLD cohort, NAS score $5 was independently
associated with female gender (OR 2.55, 95% CI 1.51–4.31,
Table 1. Baseline Demographic, Laboratory, Metabolic, and Histological Features of 366 Italian Patients with Non-alcoholic Fatty
Liver Disease.
Variable
Non-alcoholic Fatty Liver
Disease (Sicily n =197)
Non-alcoholic Fatty Liver Disease
(Center/Northern Italy n=169) P value
Mean Age – years 45.0613.3 42.2611.2 0.03
Male Gender 131 (66.5) 130 (76.9) 0.03
Mean Body Mass Index – kg/m2 29.764.6 27.864.1 ,0.001
Alanine Aminotransferase – IU/L 79.4655.1 77.8653.3 0.78
Arterial Hypertension 46 (23.3) 47 (27.8) 0.21
Type 2 Diabetes 28 (14.2) 22 (11.2) 0.39
Cholesterol – mg/dL 205.8644.8 203.4645.2 0.74
HDL Cholesterol – mg/dL 49.0615.4 47.7611.3 0.38
Triglycerides – mg/dL 147.6678.7 142.7686.9 0.57
Blood Glucose – mg/dL 96.1625.2 94.7621.5 0.56
Insulin – mU/mL 16.569.6 14.5610.6 0.08
HOMA Score 4.0362.96 3.5763.41 0.18
PNPLA3 rs738409 polymorphism
C/C 62 (31.5) 54 (31.9)
C/G 94 (47.7) 79 (46.7)
G/G 41 (20.8) 36 (21.4) 0.98
GCKR rs780094 polymorphism
C/C 32 (16.2) 28 (16.6)
C/T 99 (50.3) 80 (47.3)
T/T 66 (33.5) 61 (36.1) 0.98
Histology
Lobular inflammation
2–3
Balloning 83 (42.1) 20 (11.8) ,0.001
1–2 181 (91.8) 122 (71.7) ,0.001
Steatosis grade
1 (5%–33%) 72 (36.6) 76 (44.9)
2 (.33%–66%) 62 (31.5) 62 (36.7)
3 (.66%) 63 (31.9) 31 (18.4) 0.01
NAS$5 116 (58.8) 41 (24.2) ,0.001
Stage of Fibrosis
2–4 86 (43.6) 72 (42.6) 0.84
Abbreviation: IU, international units; HOMA, homeostasis model assessment; HDL, high density lipoprotein. Data are given as mean 6 standard deviation, or as number
of cases (%).
doi:10.1371/journal.pone.0087523.t001
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p,0.001), high BMI (OR 1.11 95% CI 1.04–1.17, p= 0.004),
HOMA (OR 1.13 95% CI 1.03–1.25, p= 0.01), and PNPLA3 GG
(OR 2.15, 95% CI 1.22–3.77, p= 0.008) at multivariate logistic
regression analysis (table 3).
Finally, the presence of significant liver fibrosis (.F1) was
independently linked to high HOMA (OR 1.12, 95% CI 1.01–
1.23, p= 0.02), NAS $5 (OR 4.09, 95% CI 2.45–6.81, p,0.001),
and GCKR C.T SNP (OR 2.06, 95% CI 1.43–2.98, p,0.001) in
the whole study population (table 3 lower panel). When
histological variables were removed from the model, .F1 fibrosis
was independently linked to female gender (OR 1.77, 95% CI
1.05–2.99, p= 0.03), BMI (OR 1.08, 95% CI 1.02–1.14,
p= 0.008), HOMA (OR 1.16, 95% CI 1.05–1.28, p= 0.004),
and GCKR C.T SNP (OR 1.88, 95% CI 1.33–2.66, p,0.001).
Figure 1 shows the stepwise increased prevalence of significant
fibrosis (.F1) according to GCKR genotype. Similar results were
observed when the NAFLD cohorts were split by center (table 3
lower panel).
Discussion
The main finding of this study on a large cohort of Italian
patients with NAFLD is the association between GCKR rs780094
C.T SNP and high triglyceride levels and the severity of liver
fibrosis, independent of other known risk factors for liver damage
The complex interplay between genetic background and
environmental factors in the development of NAFLD [26] is
progressively unveiled by the recognition of the role of specific
SNPs, such as PNPLA3 C.G SNPs. The GCKR CRT SNPs is
also emerging as an important genetic determinant of NAFLD.
This trait has been initially associated with imaging-based
diagnosis of NAFLD in a population of healthy subjects [19],
and the association has been further validated in children and in
patients of different ethnicity [20–22]. In this study, besides
confirming the associations between PNPLA3 C.G SNP and
steatosis/lobular inflammation [11–15], for the first time we also
highlighted the potential impact of GCKR CRT SNP on liver
fibrosis in an European cohort of histologically diagnosed NAFLD
patients.
Of importance, this association was independent from other
well-known determinants and the severity of liver fibrosis showed a
stepwise increase from patients carrying one risk allele to those
carrying two risk alleles. It is noteworthy that this trend was
observed in both tested cohorts. Our findings are in agreement
with the evidence of a link between GCKR CRT SNP and higher
ALT levels reported by Hernaez et al [22] in the US Health and
Nutrition Examination Survey III, and also agree with preliminary
unpublished data from FLIP cohort [30], and published data from
a small Asiatic population [31] reporting the association between
GCKR gene variant and severity of liver damage in NAFLD.
Although this study was not designed to clarify the pathogenic
link between GCKR SNPs and liver fibrosis in NAFLD, some
hypotheses can be provided. The GCKR gene product, the
glucokinase regulatory protein, acts as an inhibitor of glucokinase
(GCK) activity, a key liver enzyme for glucose metabolism, whose
hepatic concentrations are increased in fatty liver [32,33]. GCKR
rs780094 C.T SNP might facilitate liver fibrogenesis by reducing
the inhibitory effect of GCKR, thereby increasing GCK activity.
GCKR rs780094 SNP is in linkage disequilibrium with the GCKR
rs1260326 SNP, that is associated with an increased GCK liver
activity [20,34]. By inducing de novo hepatic lipogenesis and by
suppressing hepatic fatty acid oxidation, GCK liver activity
Table 2. Association of the rs780094 CRT GCKR SNP with anthropometric, biochemical, metabolic and histological features in 366
Patients with Non-alcoholic Fatty Liver Disease.
Variable GCKR CC N=60 GCKR CT n=179 GCKR TT n=127
Univariate Analysis p
value6
Mean age – years 42.2613.0 43.3612.6 44.9611.8 0.33
Males 48 127 86 0.22
Mean body mass index – kg/m2 28.564.6 28.764.4 29.164.5 0.61
Alanine aminotransferase – IU/L 81.6670.6 81.4652.1 73.4648.0 0.40
Cholesterol – mg/dL 198.6647.9 202.4640.9 209.5648.5 0.23
HDL cholesterol – mg/dL 50.2618.2 48.9613.2 47.1612.2 0.32
Triglycerides – mg/dL 139.8683.3 138.0669.8 158.3696.3* 0.09
Blood glucose – mg/dL 91.4618.6 96.6627.7 95.8618.5 0.32
Insulin – mU/mL 15.169.8 16.069.1 15.4611.5 0.78
HOMA-score 3.6563.23 3.9663.03 3.7063.05 0.68
HOMAbeta % 144.4663.7 144.6671.5 131.8661.0 0.25
Diabetes 8 21 18 0.81
Arterial hypertension 14 41 38 0.35
Steatosis grade 3 13 44 37 0.49
Lobular Inflammation Grade 2–3 17 53 34 0.86
Ballooning 46 151 105 0.39
NAS $5 24 82 51 0.54
Fibrosis .F1 17 71 70 0.001
Data are given as mean 6 SD or as number of cases. HDL: high-density lipoprotein; HOMA: homeostasis model assessment.
uby ANOVA;
*p = 0.02 versus GCKR CC/CT.
doi:10.1371/journal.pone.0087523.t002
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prompts the hepatic accumulation of triglycerides, causing organ
damage. In addition, GCKR rs780094 SNP might favor liver
fibrogenesis along two more pathways: a) by affecting the
expression of nearby genes, and specifically by increasing the
expression of C2orf16 mRNA in the liver [19]; b) by favoring a
low grade chronic inflammation as expressed by higher serum
levels of C-reactive protein [35].
In our study we also demonstrated that patient homozygous for
the T allele of GCKR had higher serum triglycerides levels, in
agreement with previous finding by Speliotes et al [19], and with
the hypothesis that the GCKR rs780094 SNP could lead to a
higher activity of liver glcokinase. In addition we also observed
higher triglycerides levels in Sicilian compared with Center/
Northern Italy cohort, probably attributable to the more
unhealthy lifestyle characterizing the southern population. By
contrast we did not identify any association between severity of
steatosis and GCKR genotype. Our data are not in contrast with
the study of Speliotes et al [19] and more recent studies showing a
Table 3. Association of the GCKR rs780094 genotype and liver damage as evaluated by unadjusted and adjusted models in 366
Patients with Non-alcoholic Fatty Liver Disease.
Sicilian Cohort n =197 Center/northern Italy Cohort n=169 Combined n=366
Variable OR (95% C.I.) P value OR (95% C.I.) P value OR (95% C.I.) P value
Steatosis (1 vs 2 vs 3)
Unadjusted Model Adjusted Model Unadjusted Model Adjusted Model Unadjusted Model Adjusted Model
Females - - - - 1.94 (1.18–3.20)
0.009
1.43 (0.83–2.44)
0.19
Mean BMI – kg/m2 1.09 (1.02–1.17)
0.006
1.08 (1.00–1.16)
0.03
1.15 (1.05–1.27)
0.003
1.12 (1.01–1.25)
0.02
1.13 (1.07–1.19)
,0.001
1.10 (1.04–1.17)
0.001
HOMA-score 1.13 (1.01–1.25)
0.02
1.08 (0.97–1.21)
0.14
1.16 (1.03–1.29)
0.01
1.08 (0.96–1.22)
0.17
1.15 (1.06–1.24)
,0.001
1.08 (1.00–1.17)
0.04
GCKR CC vs CT
vs TT
1.23 (0.79–1.91)
0.35
1.19 (0.75–1.90)
0.44
1.27 (0.72–2.25)
0.40
1.37 (0.74–2.52)
0.31
1.22 (0.87–1.73)
0.24
1.22 (0.85–1.76)
0.27
PNPLA3 CC vs
CG vs GG
2.19 (1.08–4.45)
0.02
2.12 (1.02–4.41)
0.04
2.48 (1.05–5.83)
0.03
2.50 (1.03–6.05)
0.04
2.24 (1.31–3.83)
0.003
1.97 (1.11–3.51)
0.02
NAS$5
Mean age – years - - - - 1.01 (1.00–1.03)
0.05
0.99 (0.97–1.00)
0.79
Females 2.47 (1.30–4.69)
0.006
1.69 (0.83–3.42)
0.14
3.98 (1.83–8.64)
,0.001
3.70 (1.62–8.47)
0.002
3.16 (1.97–5.06)
,0.001
2.55 (1.51–4.31)
,0.001
Mean BMI – kg/m2 1.10 (1.03–1.18)
0.003
1.05 (0.97–1.13)
0.21
1.15 (1.05–1.25)
0.002
1.13 (1.02–1.25)
0.01
1.14 (1.09–1.21)
,0.001
1.11 (1.04–1.17)
0.004
HOMA-score 1.38 (1.17–1.64)
,0.001
1.28 (1.07–1.53)
0.005
1.14 (1.02–1.27)
0.01
1.03 (0.91–1.17)
0.54
1.24 (1.12–1.36)
,0.001
1.13 (1.03–1.25)
0.01
GCKR CC vs CT
vs TT
1.14 (0.75–1.73)
0.52
1.10 (0.69–1.75)
0.67
0.76 (0.46–1.27)
0.30
0.75 (0.43–1.30)
0.31
0.96 (0.71–1.29)
0.79
0.91 (0.65–1.26)
0.58
PNPLA3 CC/CG
vs GG
3.62 (1.57–8.35)
0.002
3.06 (1.26–7.41)
0.01
2.49 (1.13–5.51)
0.02
2.31 (1.00–5.31)
0.04
2.54 (1.52–4.27)
,0.001
2.15 (1.22–3.77)
0.008
Fibrosis (0–1 versus
2–4)
Mean age – years 1.03 (1.01–1.06)
0.001
1.03 (1.00–1.05)
0.02
- - 1.02 (1.01–1.04) 0.001 1.01 (0.99–1.03) 0.28
Females 2.34 (1.28–4.29)
0.006
1.44 (0.68–3.03)
0.33
2.73 (1.30–5.71)
0.007
2.06 (0.86–4.91)
0.10
2.47 (1.55–3.93)
,0.001
1.40 (0.80–2.45) 0.23
Mean BMI – kg/m2 1.10 (1.03–1.18)
0.002
1.02 (0.94–1.11)
0.52
1.17(1.07–1.28)
,0.001
1.12 (1.01–1.23)
0.02
1.12 (1.07–1.18)
,0.001
1.05 (0.98–1.11) 0.10
HOMA-score 1.31 (1.14–1.52)
,0.001
1.15 (1.00–1.32)
0.04
1.16 (1.03–1.32)
0.01
1.06 (0.91–1.23)
0.43
1.24 (1.12–1.36)
,0.001
1.12 (1.01–1.23) 0.02
Arterial
hypertension
- - - - 1.93 (1.20–3.12) 0.007 1.36 (0.76–2.43) 0.29
NAS$5 7.83 (3.93–15.5)
,0.001
7.05 (3.22–15.4)
,0.001
5.58 (2.55–12.2)
,0.001
4.43 (1.80–10.9)
0.001
5.06 (3.23–7.93)
,0.001
4.09 (2.45–6.81)
,0.001
GCKR CC vs CT
vs TT
1.82 (1.18–2.81)
0.006
2.07 (1.22–3.49)
0.006
1.75 (1.10–2.76)
0.01
2.23 (1.31–3.82)
0.003
1.77 (1.30–2.44)
,0.001
2.06 (1.43–2.98)
,0.001
PNPLA3 CC/CG
vs GG
1.47 (0.73–2.93)
0.27
0.62 (0.26–1.49)
0.29
1.94 (0.92–4.09)
0.07
1.32 (0.54–3.18)
0.53
1.67 (1.01–2.67)
0.04
1.03 (0.56–1.87)
0.92
Unadjusted and adjusted OR were presented for PNPLA3 and GCKR SNPs, and only for clinical, metabolic and histological variables significant at univariate analysis.
PNPLA3 and GCKR SNPs, when not significant, were forced into the models.
doi:10.1371/journal.pone.0087523.t003
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link between GCKR SNP and the presence of steatosis [20–22].
We did not test subjects without steatosis of the same geographic
area, and therefore we were not able to discriminate between
presence/absence of fatty liver infiltration. Obviously, the lack of
these data could partially affect the interpretation of our results,
and in particular of the significance of the real effect of GCKR
SNP on steatosis.
Finally, we did not confirm the reported association between
PNPLA3 genotype and severity of liver fibrosis [14]. Differences in
the characteristics of the individual study cohorts could explain the
lack of association in our cohort.
The main limitation of this study lies in its cross-sectional
nature, making it impossible to dissect the temporal relation
between genetic background and progression of liver disease over
time. This issue should be tested in longitudinal analyses. A further
methodological question is the potentially limited external validity
of the results for different populations and settings. Our study
included cohorts of Italian patients enrolled at tertiary care
centers, who may be different, in terms of both metabolic features
and severity of liver disease, from the majority of prevalent cases of
NAFLD in the general population. However, validation of the
results in two independent, largely different populations from
South and Northern/Center Italy supports a general involvement
of GCKR rs780094 C.T polymorphisms in NAFLD progression.
In conclusion, this study on a large cohort of patients with
histological diagnosis of NAFLD, showed an independent link
between GCKR SNPs and significant hepatic fibrosis. Further
studies are needed to explore the pathogenic mechanisms
underlying this association.
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